



NDA 21-226/S-019

**Prior Approval Labeling Supplement**

Abbott Laboratories  
Attention: Raymond Votzmeyer  
Associate Director Global Pharmaceutical Regulatory Affairs  
Dept. RA76/Building AP30-1NE  
200 Abbott Park Road  
Abbott Park, IL 60064-6157

Dear Mr. Votzmeyer:

Please refer to your supplemental new drug application dated June 27, 2006, received June 28, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for KALETRA<sup>®</sup> (lopinavir/ritonavir capsules).

We acknowledge receipt of your submissions dated June 27, 2006, December 12, 2006, and December 15, 2006.

This supplemental new drug application provides drug interaction information when the KALETRA<sup>®</sup> tablet formulation is co-administered with ranitidine or omeprazole.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

In addition, within 21 days of the date of this letter, amend any pending applications for this NDA with content of labeling in structured product labeling (SPL) format to include the changes approved in this application.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert submitted on December 15, 2006).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-226/S-019.**" Approval of this submission by FDA is not required before the labeling is used.

If you have any questions, call Karen Winestock, Regulatory Project Manager, at (301) 796-0834.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Debra Birnkrant  
12/21/2006 10:23:25 AM  
NDA 21-226